Rusfertide
Feb 06, 2025
Polycythemia Vera: Growing Competition and the Changing Treatment Landscape in 2025
JAKAFI’s demand continues to grow in Polycythemia Vera The therapeutic paradigm for Polycythemia Vera patients has shifted significantly in the last few years. Previously, the Polycythemia Vera treatment landscape was dominated by generic medicines such as aspirin, hydroxyurea, interferons, and phlebotomy unti...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
